The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetes |
Vol/bind | 59 |
Udgave nummer | 7 |
Sider (fra-til) | 1765-70 |
Antal sider | 6 |
ISSN | 0012-1797 |
DOI | |
Status | Udgivet - 1 jul. 2010 |
ID: 33940158